The toxSYN™ platform comprises ADC payloads that span multiple modes of action and where the majority are clinically validated.  Together with the company’s other ADC enabling technologies, these offer a consolidated licensing solution for translating any antibody into a highly competitive, proprietary ADC product. 

Each toxSYN™ linker-payload is functionalized to allow facile conjugation using the company’s GlycoConnect™ technology. Furthermore, these may include linkers that are of non-cleavable or cleavable nature (i.e. designed for intracellular/lysosomal release of the active catabolite).